Literature DB >> 10431795

Anticardiolipin antibodies and occlusive vascular disease of the eye: prospective study.

C D Kalogeropoulos1, P Spyrou, M I Stefaniotou, E E Tsironi, A A Drosos, K G Psilas.   

Abstract

There is a recognized association between the presence of anticardiolipin antibodies and vascular occlusive disease. The purpose of our study is to detect the presence of high titers of anticardiolipin antibodies (ACA) in the serum and to correlate the titers with the severity of the vascular disease in patients with occlusive ocular vascular disease. 82 patients were included in a prospective study; 25 patients with anterior ischaemic optic neuropathy, 36 with retinal vein occlusion and 21 with retinal artery occlusion. ACA (IgG and IgM isotypes) were measured by ELISA in the sera of all patients. The group of the patients (group A) was compared to an age-matched control group of 79 healthy individuals (group B). IgG isotype (but not IgM) titers of ACA were found significantly higher in group A (P < 0.001). In patients with titers of ACA (IgG isotype) > 100 units we noted a higher incidence of a more severe disease (recurrency, involvement of both eyes or extraocular manifestations) especially among those with anterior ischaemic optic neuropathy and secondarily in those with retinal artery occlusion. Our results suggest that the association between high titers of ACA and occlusive vascular disease of the eye concerns only the IgG isotype. In addition, the detection of high titers of IgG/AGA in patients could be a useful marker for disease severity and prognosis and this observation seems to be more explicit in cases with arterial occlusive disease than in cases with venous occlusive disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10431795     DOI: 10.1023/a:1001131323739

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  29 in total

1.  IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.

Authors:  M E Cronin; R M Biswas; C Van der Straeton; T A Fleisher; J H Klippel
Journal:  J Rheumatol       Date:  1988       Impact factor: 4.666

2.  Brief report: treatment of vasospastic amaurosis fugax with calcium-channel blockers.

Authors:  J M Winterkorn; M J Kupersmith; J D Wirtschafter; S Forman
Journal:  N Engl J Med       Date:  1993-08-05       Impact factor: 91.245

3.  Association of HLA-Bw44 with chlorpromazine-induced autoantibodies.

Authors:  R T Canoso; M E Lewis; E J Yunis
Journal:  Clin Immunol Immunopathol       Date:  1982-11

4.  Vaso-occlusive retinopathy in the primary anti-phospholipid antibody syndrome.

Authors:  J F Acheson; R M Gregson; P Merry; W E Schulenburg
Journal:  Eye (Lond)       Date:  1991       Impact factor: 3.775

5.  Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases.

Authors:  S R Levine; M J Deegan; N Futrell; K M Welch
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

6.  Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics.

Authors:  H P McNeil; C N Chesterman; S A Krilis
Journal:  Br J Haematol       Date:  1989-12       Impact factor: 6.998

7.  High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population.

Authors:  M N Manoussakis; A G Tzioufas; M P Silis; P J Pange; J Goudevenos; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

8.  Ocular thrombosis associated with antiphospholipid antibodies.

Authors:  S L Galetta; G L Plock; M J Kushner; R E Wyszynski; A J Brucker
Journal:  Ann Ophthalmol       Date:  1991-06

9.  Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients.

Authors:  A Glacet-Bernard; N Bayani; P Chretien; C Cochard; F Lelong; G Coscas
Journal:  Arch Ophthalmol       Date:  1994-06

10.  Thrombophilic factors in ischaemic and non-ischaemic idiopathic retinal vasculitis.

Authors:  H E Palmer; K M Jurd; B J Hunt; A G Zaman; M R Stanford; M D Sanders; E M Graham
Journal:  Eye (Lond)       Date:  1995       Impact factor: 3.775

View more
  4 in total

Review 1.  Looking into the eyes of patients with antiphospholipid syndrome.

Authors:  D Yehudai; Y Shoenfeld; E Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

2.  Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor.

Authors:  Maha Shahin; Amany M El-Diasty; Mohamed Mabed
Journal:  Saudi J Ophthalmol       Date:  2009-08-05

3.  Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series.

Authors:  Evangelia Tsironi; Nikolaos Gatselis; Maria G Kotoula; Kalliopi Zachou; Maria Pefkianaki; Fani Zacharaki; Dimitrios Z Chatzoulis; George N Dalekos
Journal:  Cases J       Date:  2009-10-20

Review 4.  Ischemic retinal vasculitis and its management.

Authors:  Lazha Talat; Sue Lightman; Oren Tomkins-Netzer
Journal:  J Ophthalmol       Date:  2014-04-15       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.